Vaccine-induced Th1-type responses are dominant over Th2-type responses in the short term whereas pre-existing Th2 responses are dominant in the longer term

Scandinavian Journal of Immunology

Volumn 47, Issue 5, 1998, Pages 459-465

  Fernando, G J P ^a,c   Stewart, T J ^a   Tindle, R W ^a,b   Frazer, I H ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

^c PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

FREUND ADJUVANT; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HELPER CELL; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; WART VIRUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; IMMUNITY, CELLULAR; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS INFECTIONS; TH1 CELLS; TH2 CELLS; TIME FACTORS; TUMOR VIRUS INFECTIONS; VACCINATION;

EID: 0031799701     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00327.x     Document Type: Article

References (44)

1. Stieneker F, Kersten G, van Bloois L et al. Comparison of 24 different adjuvants for inactivated HIV-2 split whole virus as antigen in mice. Induction of titres of binding antibodies and toxicity of the formulations. Vaccine 1995;13:45-53.
2. Leenaars PP, Hendriksen CF, Koedam MA, Claassen I, Claassen E. Comparison of adjuvants for immune potentiating properties and side effects in mice. Vet Immunol Immunopathol 1995;48:123-38.
3. Bianchi AT, van der Heijden PJ, Bokhout BA. Modification of immune induction by adjuvant. Adv Exp Med Biol 1985;186:463-9.
4. McDevitt HO, Chinitz A. Genetic control of the antibody response: relationship between immune response and histocompatibility (H-2) type. Science 1969;163:1207-8.
5. Parish CR. Immune deviation: a historical perspective. Immunol Cell Biol 1996;74:449-56.
6. Gupta RK, Siber GR. Adjuvants for human vaccines - current status, problems and future prospects. Vaccine 1995;13:1263-76.
7. Sjolander A, Bengtsson KL, Morein B. Kinetics, localization and cytokine profile of T cell responses to immune stimulating complexes (iscoms) containing human influenza virus envelope glycoproteins. Vaccine 1997;15:1030-8.
8. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
9. Zaitseva M, Golding H, Manischewitz J, Webb D, Golding B. Brucella abortus as a potential vaccine candidate: induction of interleukin-12 secretion and enhanced B7.1 and B7.2 and intercellular adhesion molecule 1 surface expression in elutriated human monocytes stimulated by heat-inactivated B. abortus. Infect Immun 1996;64:3109-17.
10. Stevens TL, Bossie A, Sanders VM et al. Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature 1988;334:255-8.
11. Frazer IH. The role of vaccines in the control of STDs: HPV vaccines. Genitourin Med 1996;72:398-403.
12. Tindle RW. Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol 1996;8:643-50.
13. van Driel WJ, Ressing ME, Brandt RM et al. The current status of therapeutic HPV vaccine. Ann Med 1996;28:471-7.
14. Bosch FX, Manos MM, Munoz N et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
15. von Knebel Doeberitz M, Rittmuller C, Aengeneyndt F, Jansen-Durr P, Spitkovsky D. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions. J Virol 1994;68:2811-21.
16. Chen LP, Thomas EK, Hu SL, Hellstrom I, Hellstrom KE. Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen. Proc Natl Acad Sci USA 1991;88:110-4.
17. Jochmus I, Bouwes Bavinck JN, Gissmann L. Detection of antibodies to the E4 or E7 proteins of human papillomaviruses (HPV) in human sera by Western blot analysis: type-specific reaction of anti-HPV 16 antibodies. Mol Cell Probes 1992;6:319-25.
18. Seedorf K, Oltersdorf T, Krammer G, Rowekamp W. Identification of early proteins of the human papilloma viruses type 16 (HPV 16) and type 18 (HPV 18) in cervical carcinoma cells. EMBO J 1987;6:139-44.
19. Aida Y, Pabst MJ. Removal of endotoxin from protein solutions by phase separation using Triton X-114. J Immunol Methods 1990;132: 191-5.
20. Feltkamp MC, Smits HL, Vierboom MP et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
21. Tindle RW, Fernando GJP, Sterling JC, Frazer IH. A 'public' T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. Proc Natl Acad Sci USA 1991;88:5887-91.
22. Fernando GJP, Tindle RW, Frazer IH. T-helper epitopes of the E7 transforming protein of cervical cancer associated human papillomavirus type 18 (HPV18). Virus Res 1995;36:1-13.
23. Cole KD, Fernando-Warnakulasuriya GJP, Boguski MS et al. Primary structure and comparative sequence analysis of an insect apolipoprotein. Apolipophorin-III from Manduca sexta. J Biol Chem 1987;262:11794-800.
24. Dalsgaard K. Saponin adjuvants. 3. Isolation of a substance from Quillaja saponaria Molina with adjuvant activity in food-and-mouth disease vaccines. Arch Gesamte Virusforsch 1974;44:243-54.
25. Cooper PD, McComb C, Steele EJ. The adjuvanticity of Algammulin, a new vaccine adjuvant. Vaccine 1991;9:408-15.
26. Carbone FR, Bevan MJ. Induction of ovalbumin-specific cytotoxic T cells by in vivo peptide immunization. J Exp Med 1989;169:603-12.
27. Tindle RW, Croft S, Herd K et al. A vaccine conjugate of 'ISCAR' immunocarrier and peptide epitopes of the E7 cervical cancer-associated protein of human papillomavirus type 16 elicits specific Th1- and Th2-type responses in immunized mice in the absence of oil-based adjuvants. Clin Exp Immunol 1995;101:265-71.
28. Fernando GJP, Stenzel DJ, Tindle RW, Merza MS, Morein B, Frazer IH. Peptide polymerisation facilitates incorporation into ISCOMs and increases antigen-specific IgG2a production. Vaccine 1995;13:1460-7.
29. Dotsika E, Karagouni E, Sundquist B, Morein B, Morgan A, Villacres-Eriksson M. Influence of Quillaja saponaria triterpenoid content on the immunomodulatory capacity of Epstein-Barr virus iscoms. Scand J Immunol 1997;45:261-8.
30. + T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol 1995;25:2835-41.
31. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells [published erratum appears in Nature 1993 Jul 15;364:262]. Nature 1993;362:758-61.
32. Ramon G. Procedes por accroitre la production des anti-toxines. Ann Inst Pasteur, Paris 1926;40:1-10.
33. Higuchi R, Tokimutsu Y, Komori T. An acylated triterpinoid saponin from Quillaja saponaria. Phytochemistry 1988;27:1165-8.
34. Jackson LA, Opdebeeck JP. The effect of various adjuvants on the humoral immune response of sheep and cattle to soluble and membrane midgut antigens of Boophilus microplus. Vet Parasitol 1995;58:129-41.
35. + cytotoxic T cells. Vaccine 1994;12:73-80.
36. Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984;308:457-60.
37. Barr IG, Mitchell GF. ISCOMs (immunostimulating complexes): the first decade. Immunol Cell Biol 1996;74:8-25.
38. Kensil CR. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 1996;13:1-55.
39. Bomford R, Stapleton M, Winsor S, McKnight A, Andronova T. The control of the antibody isotype response to recombinant human immunodeficiency virus gp120 antigen by adjuvants. AIDS Res Hum Retroviruses 1992;8:1765-71.
40. Germann T, Bongartz M, Dlugonska H et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995;25:823-9.
41. Hayglass KT, Gieni RS, Stefura WP. Long-lived reciprocal regulation of antigen-specific IgE and IgG2a responses in mice treated with glutaraldehyde-polymerizedovalbumin. Immunology 1991;73:407-14.
42. Brewer JM, Conacher M, Satoskar A, Bluethmann H, Alexander J. In interleukin-4-deficient mice, alum not only generates T helper 1 responses equivalent to Freund's complete adjuvant, but continues to induce T helper 2 cytokine production. Eur J Immunol 1996;26: 2062-6.
43. Sacks T, Klinman DM. Long-term effect of primary immunization on subsequent immune responsiveness. Cell Immunol 1997;177: 162-8.
44. Scott DE, Agranovich I, Inman J, Gober M, Golding B. Inhibition of primary and recall allergen-specific T helper cell type 2-mediated responses by a T helper cell type 1 stimulus. J Immunol 1997;159: 107-16.